Dianthus Therapeutics (DNTH) Projected to Post Quarterly Earnings on Thursday

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) will likely be announcing its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.86) per share and revenue of $0.81 million for the quarter.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The firm had revenue of $1.33 million for the quarter, compared to analysts' expectations of $1.40 million. On average, analysts expect Dianthus Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Dianthus Therapeutics Stock Down 3.9 %

Shares of NASDAQ:DNTH traded down $0.85 during trading on Tuesday, hitting $20.70. The stock had a trading volume of 100,871 shares, compared to its average volume of 263,560. Dianthus Therapeutics has a 12 month low of $13.37 and a 12 month high of $32.27. The company has a market capitalization of $665.10 million, a PE ratio of -8.32 and a beta of 1.48. The firm's fifty day moving average is $19.87 and its 200 day moving average is $22.59.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Guggenheim reiterated a "buy" rating and issued a $84.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. HC Wainwright restated a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, Wedbush reiterated an "outperform" rating and set a $36.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $54.33.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.